Financial Report: Amgen 3Q

Amgen 3Q

3Q Revenues: $3.8 billion (+1%)

3Q Earnings: $1.2 billion (-11%)

YTD Revenues: $11.2 billion (+3%)

YTD Earnings: $3.6 billion (-2%)

Comments: Sales in the U.S. were flat at $2.9 billion in the quarter and sales included a $64 million unfavorable impact due to U.S. Health Care Reform. International sales were up 2% to $838 million. Foreign exchange rates negatively impacted sales in the quarter by $16 million. Worldwide sales of Aranesp were down 9% to $623 million due to a decrease in demand. Sales of Epogen were $653 million (-2%). Combined worldwide sales of Neulasta and Neupogen were $1.3 billion (+4%). Enbrel sales were $914 million (-1%). Sensipar sales were up 6% to $175 million. R&D expenses were up 12% in the quarter to $689 million.